Equillium, Inc. (EQ)

Over the past six months, Equillium's stock has trended upwards. Key events impacting the stock price include earnings reports, private placement financings, insider selling by Christine Zedelmayer, and analyst coverage from Roth Capital, Stifel Nicolaus, and Wall Street Zen.

Equillium, Inc. does not experience traditional product demand seasonality as a clinical-stage biotechnology company without approved products on the market. The "seasonality" of its business is more closely tied to the cyclical nature of clinical development, including the initiation and readout of clinical trial data, regulatory milestones, and financing activities.

Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory disorders. The company's core business revolves around advancing a pipeline of novel immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its major product candidates include Itolizumab (EQ001), EQ504, EQ302, and EQ101.

Equillium, Inc. is headquartered in La Jolla, California, United States, and plans for global market expansion through strategic partnerships and collaborations.

Equillium's brand reputation is mixed but leans towards positive. Events that have influenced its standing include positive clinical data, mixed clinical trial results, an FDA decision, financing successes, and a strategic focus shift.

Equillium, Inc. has 41 institutional owners and shareholders holding a total of 37,112,970 shares. Institutional investors own 57.95% of the stock, Equillium insiders own 23.48%, and retail investors own 18.56%. Major institutional owners include Janus Henderson Group Plc, ADAR1 Capital Management, LLC, and Adage Capital Partners Gp, L.l.c. Key individual owners include Daniel Bradbury and Bruce D. Steel.